王军舰

王军舰

教授

研究领域：1. 肿瘤治疗可药性新靶点及先导药物发现;2. 癌细胞与神经、免疫细胞互作调控机制;3. 肿瘤耐药、转移驱动机制

联系邮箱： wangjj87@mail.sysu.edu.cn

联系方式

电子邮箱：wangjj87@mail.sysu.edu.cn

办公地址：中国广州大学城外环东路132号bm11222宝马娱乐网站429室，邮编：510006

 

简单介绍

王军舰博士，bm11222宝马娱乐网站教授、博士生导师，广东省成药性评估及评价工程实验室副主任，广东省粤港澳研究团队带头人，广东省杰出青年基金获得者，中山大学“百人计划二期”青年杰出人才。主要从事肿瘤药理学和抗肿瘤创新药物研究工作，致力于发现和确证可药性肿瘤治疗新靶点，研发抗肿瘤创新药物，探索肿瘤耐药性和转移作用机制，为癌症治疗提供新策略。在 Nature Medicine, Cell Rep Med，Embo mol Med, J Am Chem Soc，Mol Ther等国际专业权威期刊发表研究性论文70余篇。获授权专利8项。获得2016年国际前列腺癌基金会Challenge Award。兼任 Cell Biology International 杂志副主编（Associate Editor）、《药学学报》及 Acta Pharmaceutica Sinica B青年编委、广东省药理学会理事、广东省药理学会海洋药物药理专业委员会（筹）主任委员、药物筛选与评价专业委员会 & 抗炎免疫专业委员会副主任委员、中国药理学会肿瘤药理专业委员会委员。

 

招生招聘信息

  1. 课题组长期招聘具有药理学、肿瘤学、化学生物学或分子细胞生物学背景，对肿瘤药理学和抗肿瘤创新药物研发感兴趣的博士后和专职研究员，课题组将提供额外每年5-10万津贴。

研究方向

1. 肿瘤治疗可药性新靶点及先导药物发现

2. 癌细胞与神经、免疫细胞互作调控机制

3. 肿瘤耐药、转移驱动机制

教育经历

2006年9月至2009年6月 博士 中国科学院广州生物医药与健康研究院

2007年8月至2007年10月 MERIT Student 香港中文大学

2002年9月至2005年6月 硕士 中山大学

1998年9月至2002年6月 学士 内蒙古大学

 

工作经历

2017年9月 至今 教授 bm11222宝马娱乐网站

2014年9月 至 2017年8月 助理科学家 美国加利福尼亚大学戴维斯分校

2010年5月 至 2014年8月 博士后 美国加利福尼亚大学戴维斯分校

2009年7月 至 2009年12月 助理研究员 中国科学院广州生物医药与健康研究院

2005年7月 至 2006年8月 研究助理 中国科学院广州生物医药与健康研究院

 

社会/学术任职

Cell Biology International（Wiley），副主编

Acta Pharmaceutica Sinica B及《药学学报》，青年编委

美国癌症协会（AACR），会员

国家自然科学基金函评专家

中国药理学会表观遗传药理专业委员会，委员

中国药理学会抗炎免疫药理专业委员会，委员

中国抗癌协会抗癌药物专业委员会，委员

广东省药理学会药物筛选与评价专业委员会，副主任委员

广东省药理学会抗炎免疫药理专业委员会，副主任委员

广东省药理学会，理事

 

承担纵向科研项目

1. 国家自然科学基金面上项目，2023.01-2026.12，项目负责人 ，52万元，在研

2. 广东省自然科学基金粤穗联合-粤港澳团队项目，2023.10-2026.09，项目负责人，200万元，在研

3. 广东省科技计划项目-粤港澳联合创新领域项目，2023.01-2024.12，项目负责人，100万元，在研

4. 中山大学高校基本科研业务费学科交叉团队项目，2024.01-2026.12，项目负责人，50万元，在研

5. 广州医科大学附属第六医院开放课题-重点项目，2023.02-2027.01，项目负责人，50万元，在研

6. 国家自然科学基金面上项目，2019.01-2022.12，项目负责人 ，57万元，结题

7. 广东省杰出青年基金项目，2019.10-2023.09，项目负责人，100万元，结题

8. 广州市民生科技攻关项目，2020.03-2023.02，合作方负责人，结题

 

论著专利

代表性论文

  1. Junjian Wang, June X. Zou, Xiaoqian Xue, Demin Cai1, Yan Zhang, Zhijian Duan, Qiuping Xiang, Joy C. Yang, Maggie C. Louie, Alexander D. Borowsky, Allen C. Gao, Christopher P. Evans, Kit S. Lam, Jianzhen Xu, Hsing-Jien Kung, Ronald M. Evans, Yong Xu, and Hong-Wu Chen. 2016 ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nature Medicine. 22(5):488-96 doi:10.1038/nm.4070. (This paper is highlighted in NATURE, 532, 9, 2016 and NATURE REVIEWS UROLOGY, 13, 237, 2016)
  2. Jianwei Zheng#, Qianqian Wang#, Jianghe Chen, Guodi Cai, Zhenhua Zhang, Hongye Zou, June X Zou, Qianqian Liu, Hong Li, Sheng Li, Hong-Wu Chen, LinLin Lu, Yangiu Yuan*, Peiging Liu*, Juniian Wang*. 2024 Tumor mitochondrial oxidative phosphorylation stimulated by the nuclear receptor RORy represents an effective therapeutic opportunity in osteosarcoma, Cell Rep Med. 2024. Apr 24:101519
  3. Hong Wang, Huizi Sun, Jie Huang, Zhenhua Zhang, Guodi Cai, Chaofan Wang, Kai Xiao, Xiaofeng Xiong, Jian Zhang, Peiqing Liu, Xiaoyun Lu*, Weineng Feng*, Junjian Wang*. 2024, Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer, EMBO Molecular Medicine, Accept.
  4. Qianqian Liu#, Junhua Wang#, Huizi Sun, Zhenhua Zhang, Hong Wang, Shuai Ma, Chenxi Zhang, Qianqian Wang, Guodi Cai, Jianwei zheng, Yichu Nie*, Peiqing Liu*, Junjian Wang*. 2024 Targeting RORγ inhibits the growth and metastasis of hepatocellular carcinoma, Molecular Therapy, 2024 Mar 6;32(3):749-765. doi: 10.1016/j.ymthe.2024.01.032.
  5. Jia-Luo Huang, Xue-Long Yan, Wei Li, Run-Zhu Fan, Shen Li, Jianghe Chen, Zhenhua Zhang, Jun Sang, Lu Gan, Gui-Hua Tang, Hongwu Chen, Junjian Wang*, Sheng Yin*. 2022 Discovery of Highly Potent Daphnane Diterpenoids Uncovers Importin-β1 as a Druggable Vulnerability in Castration-Resistant Prostate Cancer, J Am Chem Soc, 2022 Sep 14. doi: 10.1021/jacs.2c06449

近年其他通讯或一作论文

  1. Jie Huang, Shi-Ling Zhang, Chao Zhang, Weiye Huang, Zhenhua Zhang, Yu-Qing Chen, Jun-Wei Su, Hong-Hong Yan, Hua-Jun Chen, Jin-Ji Yang, Junjian Wang*, Yi-Long Wu*. 2024 Genotyping of RB1 status identifies two distinct subtypes in EGFR-mutant lung cancers with SCLC transformation, Clin Transl Med, 2024 May;14(5):e1683. doi: 10.1002/ctm2.1683.
  2. Hong Wang, Qianqian Wang, Guodi Cai, Zhijian Duan, Zoann Nugent, Jie Huang, Jianwei Zheng, Alexander D. Borowsky, Jian Jian Li, Peiqing Liu, Hsing-Jien Kung, Leigh Murphy, Hong-Wu Chen*, Junjian Wang*. 2022 Nuclear TIGAR mediates an epigenetic and metabolic autoregulatory loop via Nrf2 in cancer therapeutic resistance, Acta Pharmaceutica Sinica B, 12(4): 1871-1884.
  3. Shaoqiang Guo, Miaomiao Miao, Yufeng Wu, Qinyan Wu, Dongyue Pan, Zhanfang Kang, Jianwen Zeng, Chengfei Liu*, Guoping Zhong*, Junjian Wang*, 2024 DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer, Oncogene. 2024 May;43(19):1399-1410.
  4. Chenxi Zhang#, Xiaojuan Wang#, Guodi Cai, Hong Wang, Qianqian Liu, Shuai Ma, Huizi Sun, Yana An, Miaomiao Miao, Sheng Yin, Peiqing Liu, Xiaolu Wang*, Junjian Wang*. 2024 Targeting KPNB1 with genkwadaphnin suppresses gastric cancer progression through the Nur77-mediated signaling pathway. Eur J Pharmacol. 2024 May 30:176697.
  5. Wei Fang, Jianwei Zheng, Lin Deng, Yana An, Deqin Rong, Jianwei Wei, Xiao-Feng Xiong, Junjian Wang*, Yuanxiang Wang*. 2024 Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer, J Med Chem. 2024 Jan 25;67(2):1481-1499.
  6. Jia-Luo Huang, Xue-Long Yan, Dong Huang, Lu Gan, Huahua Gao, Run-Zhu Fan, Shen Li, Fang-Yu Yuan, Xinying Zhu, Gui-Hua Tang, Hong-Wu Chen, Junjian Wang*, Sheng Yin*, Discovery of a highly potent and orally available importin-β1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer, Acta Pharmaceutica Sinica B, 2023, 2023 Dec;13(12):4934-4944.
  7. Zongbo Feng, Chunju Yang, Yi Zhang, Huaxuan Li, Wei Fang, Junhua Wang, Yichu Nie, Chang-Yun Wang, Zhiqing Liu, Zhimin Jiang, Junjian Wang*, Yuanxiang Wang*.2023, Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.  J Med Chem. 2023 Jun 2. doi: 10.1021/acs.jmedchem.3c0041.
  8. Jianghe Chen, Yiwei Hu, Jian Zhang, Qianyu Wang, Xiongzhi Wu, Weiye Huang, Qianqian Wang, Guodi Cai, Hong Wang, Tianmiao Ou, Weineng Feng, Peiqing Liu, Yonghong Liu, Junfeng Wang, Jie Huang, Junjian Wang*. 2022, Therapeutic targeting RORγ with natural product N-hydroxyapiosporamide for small cell lung cancer by reprogramming neuroendocrine fate. Pharmacol Res. 2022, Mar 5;106160.
  9. Lin Zhong, Bin Yang, Zhenhua zhang, Junfeng Wang, Xiaojuan Wang, Yinfeng Guo, Weifeng Huang, Qianqian Wang, Guodi Cai, Fan Xia, Shengning Zhou, Shuai Ma, Yichu Nie, Jinping Lei, Min Li, Peiqing Liu, Wenbin Deng, Yonghong Liu, Fanghai Han*, Junjian Wang*. Targeting autophagy peptidase ATG4B with a novel natural product inhibitor Azalomycin F4a for advanced gastric cancer. cell death & disease. 2022 Feb 18;13(2):161.
  10. Xiaowei Luo*, Guodi Cai, Yinfeng Guo, Chenghai Gao, Weifeng Huang, Zhenhua Zhang, Humu Lu, Kai Liu, Jianghe Chen, Xiaofeng Xiong, Jinping Lei, Xuefeng Zhou*, Junjian Wang*, Yonghong Liu*. 2021 Exploring Marine-Derived Ascochlorins as Novel Human Dihydroorotate Dehydrogenase Inhibitors for Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 64(18):13918-13932. (Supplementary Journal Cover)
  11. Hong Wang, Zhe Chang, Guo-di Cai, Ping Yang, Jiang-he Chen, Shan-shu Yang, Yin-feng Guo, Ming-yu Wang, Xue-hua Zheng, Jin-ping Lei, Pei-qing Liu, De-peng Zhao* & Jun-jian Wang*，2021 The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants. Acta Pharmacol Sin., 2021 Jul 28 doi: 10.1038/s41401-021-00738-w
  12. Liu-shan Chen, Meng Zhang, Peng Chen, Xiao-feng Xiong, Pei-qing Liu, Hai-bin Wang, Jun-jian Wang* & Juan Shen*. 2021 The m6A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG. Acta Pharmacol Sin. 2021 Aug 30. doi: 10.1038/s41401-021-00756-8. 
  13. Yuhui Xie, Lang Guo, Jie Huang, Xiaolong Huang, Ziwen Cong, Qianqian Liu, Qianshu Wang, Xiaoyan Pang, Songtao Xiang, Xuefeng Zhou, Liu Yonghong*, Wang Junjian*, Wang Junfeng*. Cyclopentenone-Containing Tetrahydroquinoline and Geldanamycin Alkaloids from Streptomyces malaysiensis as Potential Anti-Androgens against Prostate Cancer Cells. J Nat Prod. 2021 Jul 6. doi: 10.1021/acs.jnatprod.1c00297.
  14. Zhenhua Zhang, Yidi Zhang, Chunju Yang, Qianyu Wang, Hong Wang, Yanting Zhang, Wenbin Deng, Yichu Nie, Yonghong Liu, Xiaowei Luo*, Jie Huang*, Junjian Wang*. 2021 Antitumor effects of 3-bromoascochlorin on small cell lung cancer via inhibiting MAPK pathway. Cell Biol Int. 2021 Jul 21. doi: 10.1002/cbin.11674.
  15. Su Zhou, Qianqian Liu, Ming Bao, Jie Huang*, Junjian Wang*, Wenhao Hu and Xinfang Xu*. Gold(i)-catalyzed redox transformation of o-nitroalkynes with indoles for the synthesis of 2,3′-biindole derivatives. Org. Chem. Front., 2021,8,1808.DOI: 10.1039/d1qo00134e 
  16. Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xaiolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu*, Fanghai Han*, Junjian Wang*. 2020 Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin, Acta Pharmaceutica Sinica B, 10(12), 2313-2322 
  17. Qianqian Wang, Jianwei Zheng, June X. Zou, Jianzhen Xu, Fanghai Han, Songtao Xiang, Peiqing Liu, Hong-Wu Chen*, Junjian Wang*. 2020, S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis. Chem Biol Interact. 2020 Jan 27:108965. doi: 10.1016/j.cbi.2020.108965.
  18. Wei-Hao Chen, Kun-Long Li, Xiu-Ping Lin, Sheng-Rong Liao, Bin Yang, Xue-Feng Zhou, Jun-Jian Wang*, Yong-Hong Liu*, and Jun-Feng Wang*. 2020, Antioxidant CPA-type indole alkaloids produced from the deep-sea derived fungus Aspergillus sp. SCSIO41024. Natural Product Research. 2020 Apr 7:1-5. doi: 10.1080/14786419.2020.1749614.
  19. Menghan Gao, Lang Guo, Hong Wang, Jialuo Huang, Fanghai Han, Songtao Xiang*, Junjian Wang*. 2020, Orphan Nuclear Receptor RORγ Confers Doxorubicin Resistance in Prostate Cancer. Cell Biology International, 44(10):2170-2176. doi: 10.1002/cbin.11411.
  20. Jing Lu, Jingyan Li, Yuehuai Hu, Dayue Darrel Duan, Zhen Guo, Duanping Sun, Panxia Wang, Kaiteng Guo, Si Gao, Jianmin Jiang, Junjian Wang*, Peiqing Liu*, 2019 Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation, Acta Pharmaceutica Sinica B, 9(4): 782-793.
  21. Junjian Wang, June X. Zou, Hong Wang, Zhijian Duan, Haibin Wang, Peng Chen, Peiqing Liu, Jianzhen Xu, Hong-Wu Chen, 2019, Histone methyltransferase NSD2 mediates survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling, Acta Pharmacol Sin. 2019 40(8):1067-1075.
  22. Xiao‐Wei Luo, Cheng‐Hai Gao, Fang‐Hai Han, Xian‐Qiang Chen, Xiu‐Ping Lin, Xue‐Feng Zhou, Jun‐Jian Wang*, Yong‐Hong Liu*. 2019, A new naphthopyranone from the sponge‐associated fungus Penicillium sp. XWS02F62. Magnetic Resonance in Chemistry. https://doi.org/10.1002/mrc.4930
  23. Jing Yuan, Huiqi Hong, Yuhong Zhang, Jing Lu, Youhui Yu, Xueying Bi, Junjian Wang*, Jiantao Ye*, 2019, Chrysophanol attenuated isoproterenol-induced cardiac hypertrophy through inhibiting JAK2/STAT3 signaling pathway. Cell Biology International, doi: 10.1002/cbin.11146. 
  24. Junjian Wang, Haibin Wang, Lingyu Wang, Demin Cai, Zhijian Duan, Yanhong Zhang, Peng Chen, June X. Zou, Jianzhen Xu, Xinbin Chen, Hsing-Jien Kung, Hong-Wu Chen. 2016 Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death&Differentiation. doi: 10.1038/cdd.2016.92.                                                 
  25. Junjian Wang, Zhijian Duan, Zoann Nugent, June X. Zou, Alexander D. Borowsky, Yanhong Zhang, Clifford G. Tepper, Jian Jian Li, Oliver Fienh, Jianzhen Xu, Leigh Murphy, Hsing-Jien Kung and Hong-Wu Chen. 2016 Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Cancer Letters. 378(2):69-79. doi: 10.1016/j.canlet.2016.05.004.                                                                                                                                       合作论文代表
  26. Jiao-jiao Yu, Dan-dan Zhou, Xiao-xiao Yang, Bing Cui, Fengwei Tan, Junjian Wang, Ke Li, Shuang Shang, Cheng Zhang, Xiao-xi Lv, Xiao-wei Zhang, Shan-shan Liu, Jin-mei Yu, Feng Wang, Bo Huang, Fang Hua, and Zhuowei Hu. 2020, TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target. Nature Communications. 2020 Jul 21;11(1):3660. doi: 10.1038/s41467-020-17385-0
  27. Demin Cai, Junjian Wang, Bei Gao, Jin Li, Feng Wu, June X. Zou, Jianzhen Xu, Yuqian Jiang, Hongye Zou, Zenghong Huang, Alexander D. Borowsky, Richard J. Bold, Primo N. Lara, Jian Jian Li, Xinbin Chen, Kit S. Lam, Ka-Fai To, Hsing-Jien Kung, Oliver Fiehn, Ruqian Zhao, Ronald M. Evans & Hong-Wu Chen. 2019 RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. Nature Communications, OCT 11; 10(1): 4621. 
  28. Yan Zhang, Xishan Wu, Xiaoqian Xue, Chenchang Li, Junjian Wang, Rui Wang, cheng Zhang, Chao Wang, Yudan Shi, Lingjiao Zou, Qiu Li, Zenghong Huang, Xiaojuan Hao, Kerry M. Loomes, Donghai Wu, Hongwu Chen, Jinxin Xu, and Yong Xu, 2019，Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer (CRPC). J Med Chem. 2019 Apr 9. doi: 10.1021/acs.jmedchem.9b00327.

 

备注 * Corresponding author

所有发表论文

ORCID：https://orcid.org/0000-0002-5328-2908

专利

  1. 4-羟基-2-吡啶酮生物碱在制备治疗胃癌药物中的应用；专利申请号：202310074792.6；王军舰,张晨曦,王红,蔡国弟,王晓璐；授权有效（20240126-20440125）
  2. 一种吲哚类化合物及其合成方法和应用；专利号：ZL201910519513.6；赵德鹏，王军舰，常喆，王红；授权有效（2021.10.01-2041.09.30）。
  3. 一种G9a/GLP共价抑制剂及其制备方法及应用；专利号：CN202210738401.1；王元相, 王军舰，冯宗博，杨春菊，刘培庆；授权有效（20230929-20420928）
  4. 一种双吡啶甲酸酯类衍生物及其应用；专利申请号：2024106407481； 王军舰，安亚娜，钱宇，赵磊，刘培庆；在审（申请日：20240522）
  5. 蛋白降解靶向嵌合体及其应用；专利申请号：202310314324.1；   陆小云,王军舰,王超凡,王红；在审（申请日：20230328）

 

获奖情况

2016 前列腺癌基金会Challenge Award